Experience

• Ms. Hogan has represented: 

  • Ratio Therapeutics, a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, on its exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
  • Seaport Therapeutics, a clinical-stage biopharmaceutical dedicated to advancing novel neuropsychiatric medicines, in its spin-off from PureTech Health and $100 Million Series A financing round.
  • Verve Therapeutics in a research collaboration with Eli Lilly and Company focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
  • Voyager Therapeutics, a biotechnology company dedicated to advancing neurogenetic medicines, in its strategic collaboration agreement with Neurocrine Biosciences to advance multiple gene therapies for the treatment of neurological diseases; and its strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
  • Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics, in a strategic collaboration with Swedish Orphan Biovitrum AB (Sobi) valued at up to $1.25 billion to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need.
  • Arbor Biotechnologies, an early-stage life sciences company focused on genetic medicines, in its strategic partnership with 4D Molecular Therapeutics focused on treating large market diseases; strategic research collaboration agreement with Vertex Pharmaceutical valued at up to $1.2 billion; strategic research collaboration with TCR2 Therapeutics focused on the development of allogeneic TRuC-T cell therapies; and worldwide non-exclusive license agreement with EdiGene to advance Ex Vivo engineered cell therapy programs.
  • Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, in its multi-target research collaboration with Pfizer valued at up to $1.35 billion.
  • Benu Networks, a leading software and solutions provider, in its acquisition by Ciena Corporation.
  • Charles River Laboratories in a multiyear strategic partnership with Valo Health to offer a transformative, artificial intelligence (AI)-enabled drug discovery and development platform.
  • Nuance Communications in its strategic partnership with Microsoft aimed at accelerating the delivery of ambient clinical intelligence (ACI) technologies to reduce clinician burnout.
  • Transgene SA, a French biotech company focused on developing virus-based immunotherapies for cancer and infectious diseases, in its strategic collaboration with AstraZeneca to develop innovative oncolytic virus immunotherapies.
  • Voyager Therapeutics, a gene therapy company developing treatments for next-generation adeno-associated virus capsids, in its license option agreement with Novartis to develop first-in-class gene therapies for neurological disorders, and its licensing agreement with Pfizer focused on the development of TRACER AAV capsids.